GlassScriptPhysician profile
Elliot H Stokar
NPI 1699735738
$965.42
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $115.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $242.94 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $136.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $126.71 | 2019 | |
| Mylan Specialty L.P. | $76.86 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $51.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.02 | 2019 | |
| Philips North America LLC | $39.23 | 2019-2020 | |
| Janssen Biotech, INC. | $37.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.35 | 2019 | |
| Insmed, INC. | $29.26 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $25.88 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.72 | 2020 | |
| Sunovion Pharmaceuticals INC. | $20.76 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.01 | 2020 | |
| Electromed, INC. | $17.24 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $16.79 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.31 | 2019 | |
| Hospira, INC. | $12.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Stokar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.